Sandip Patel, MD
Medical Oncologist
Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma
Biological Therapy/Immunotherapy Brachytherapy Chemotherapy Gene Therapy Pain Management Photodynamic Therapy Radiation Therapy Targeted Therapy
Dr. Sandip Patel graduated from the Baylor College of Medicine and completed his residency program at the UCLA Medical Center. Then, he did a fellowship at the Duke University Hospital. He is specialized in Medical Oncology and board certified in Internal Medicine, Hematology and Oncology. Dr. Patel has been in practice for more than 6 years and is affiliated with the UC San Diego Health System. During his career, he has also contributed to 8 clinical research publications.
Baylor College of Medicine
Medical School
UCLA Medical Center
Residency
Duke University Hospital
Fellowship
American Board of Internal Medicine
American Board of Internal Medicine - Hematology
American Board of Internal Medicine - Oncology
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
Patel, S. P.,Kurzrock, R.; Mol. Cancer Ther.. 2015 Feb 20.
See more >>CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.
Osada, T.,Patel, S. P.,Hammond, S. A.,Osada, K.,Morse, M. A.,Lyerly, H. K.; Cancer Immunol. Immunother.. 2015 Mar 07.
See more >>Best practices for the Management of Local-regional Recurrent Chordoma. A Position Paper by the Chordoma Global Consensus Group.
Stacchiotti, S.,Gronchi, A.,Fossati, P.,Akiyama, T.,Alapetite, C.,Baumann, M.,Blay, J. Y.,Bolle, S.,Boriani, S.,Bruzzi, P.,Capanna, R.,Caraceni, A.,Casadei, R.,Colia, ...; Ann. Oncol.. 2017 Feb 12. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-
See more >>